TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Zhaoke Ophthalmology Ltd. ( (HK:6622) ).
Zhaoke Ophthalmology Limited has entered into three distribution agreements with Interpharma to commercialize NVK002, BRIMOCHOL™ PF, and six glaucoma drugs in Thailand. These agreements grant Interpharma exclusive rights to import, distribute, and sell these products, potentially enhancing Zhaoke’s market presence in Southeast Asia and expanding access to innovative ophthalmic treatments.
More about Zhaoke Ophthalmology Ltd.
Zhaoke Ophthalmology Limited is a company focused on the ophthalmology industry, providing innovative treatments and generic drugs for eye conditions. Their primary products include NVK002 for myopia progression control, BRIMOCHOL™ PF for presbyopia, and several drugs targeting glaucoma.
YTD Price Performance: 28.33%
Average Trading Volume: 2,643,883
Technical Sentiment Signal: Buy
Current Market Cap: HK$852M
For detailed information about 6622 stock, go to TipRanks’ Stock Analysis page.